Saturday, Incyte's Phase 3 frontMIND Trial Of Tafasitamab (Monjuvi/Minjuvi) And Lenalidomide Added To R-CHOP Showed A 25% Reduction In Risk Of Disease Progression Or Death Versus R-CHOP For Previously Untreated Diffuse Large Or High-grade B-cell Lymphoma

뉴스 본문을 불러오고 있어요.

Saturday, Incyte's Phase 3 frontMIND Trial Of Tafasitamab (Monjuvi/Minjuvi) And Lenalidomide Added To R-CHOP Showed A 25% Reduction In Risk Of Disease Progression Or Death Versus R-CHOP For Previously Untreated Diffuse Large Or High-grade B-cell Lymphoma | 웨이프 WAPE

Saturday, Incyte's Phase 3 frontMIND Trial Of Tafasitamab (Monjuvi/Minjuvi) And Lenalidomide Added To R-CHOP Showed A 25% Reduction In Risk Of Disease Progression Or Death Versus R-CHOP For Previously Untreated Diffuse Large Or High-grade B-cell Lymphoma

기사 요약

관련 종목

댓글 —